HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
ABCL
AbCellera Biologics Inc
Healthcare Biotechnology · British Columbia, Canada · Reports in usd
Market Cap: $3.48B
Market Cap
$3.48B
Enterprise Val
$3.04B
P/E Ratio
-21.11
P/B Ratio
3.88
Trailing PEG (1Y)
-0.42
As Of
Aug 13, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value$896.0M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-17.49%
Return on Assets-12.36%
Current Ratio12.77
Debt/Equity0.15
LT Debt/Equity0.15
Revenue Per Share0.01

Income Statement

Jun 30, 2026
Revenue$4.1M
Cost of Revenue$0.00
Gross Profit$4.1M
R&D$46.0M
SG&A$13.9M
Operating Expenses$66.8M
Operating Income-$62.8M
Interest Expense$42.0K
Tax Expense-$3.5M
Net Income-$55.4M
EPS (Basic)$-0.18
EPS (Diluted)$-0.18
EBIT-$58.9M
EBITDA-$50.1M
Consolidated Income-$55.4M
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2026
Cash & Equivalents$145.1M
Accounts Receivable$18.6M
Inventory$0.00
Current Assets$679.2M
LT Investments$65.2M
Property, Plant & Equipment$416.7M
Intangibles$84.3M
Non-Current Assets$628.3M
Total Assets$1.31B
Accounts Payable$32.5M
Current Debt$0.00
Current Liabilities$53.2M
LT Debt$129.9M
Non-Current Liabilities$358.4M
Total Liabilities$411.6M
Total Debt$129.9M
Retained Earnings-$128.1M
Shareholder Equity$896.0M
Shares Outstanding305,375,393

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow$25.9M
Investing Cash Flow$11.3M
Financing Cash Flow$6.4M
CapEx-$2.1M
Free Cash Flow$23.8M
Depreciation & Amort.$8.8M
Stock-Based Comp$12.3M
Acquisitions / Disposals$0.00
Investment Activity$7.9M
Debt Issued/Repaid-$7.2M
Equity Issued/Repaid$0.00
Dividends Paid$0.00
Net Change in Cash$43.2M
Data cached · Meta live · Daily live · Statements live · TTL 24h